Biopharma Daily Stock Updates - 01/04/21

$XBI $140.95 (+0.12%) 📈

COVID:

$ARCT (+12.72%) - Arcturus Therapeutics Receives FDA Allowance to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate in the United States

https://ir.arcturusrx.com/news-releases/news-release-details/arcturus-therapeutics-receives-fda-allowance-proceed-phase-2

$MRNA (+6.95%) - Moderna Provides COVID-19 Vaccine Supply Update

https://investors.modernatx.com/news-releases/news-release-details/moderna-provides-covid-19-vaccine-supply-update

PIPELINE:

$AYLA (+2.36%) - Ayala Pharmaceuticals to Accelerate Development of AL102 for the Treatment of Desmoid Tumors in Pivotal Phase 2/3 Study

https://ir.ayalapharma.com/news-releases/news-release-details/ayala-pharmaceuticals-accelerate-development-al102-treatment

$CALA (-44.60%) - Calithera Biosciences Reports CANTATA Study of Telaglenastat in Renal Cell Carcinoma Did Not Achieve Primary Endpoint

https://ir.calithera.com/news-releases/news-release-details/calithera-biosciences-reports-cantata-study-telaglenastat-renal

$ENDP (+4.18%) - Endo Launches Authorized Generic Version of Amitiza® (lubiprostone) Capsules in the United States

https://investor.endo.com/news-releases/news-release-details/endo-launches-authorized-generic-version-amitizar-lubiprostone

$PAND (+47.74%) - Pandion Therapeutics Announces Positive Top-Line Phase 1a Clinical Data Showing PT101 was Well-Tolerated and Selectively Expanded Regulatory T cells

https://investors.pandiontx.com/news-releases/news-release-details/pandion-therapeutics-announces-positive-top-line-phase-1a

$PRVB (+7.79%) - Provention Bio Announces U.S. FDA Filing of a Biologics License Application (BLA) and Priority Review for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-risk Individuals

http://investors.proventionbio.com/2021-01-04-Provention-Bio-Announces-U-S-FDA-Filing-of-a-Biologics-License-Application-BLA-and-Priority-Review-for-Teplizumab-for-the-Delay-or-Prevention-of-Clinical-Type-1-Diabetes-in-At-risk-Individuals